First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, log in before proceeding.

For technical support, please send an email to: education@acmg.net  or call 301-718-9603.

Or click on the "Help"  icon on the left-hand side of your screen for more information.

ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series

Therapy-related Neoplasms: Diagnosis and Clinical Perspectives

Date of Release: October 28, 2022

Expiration Date: October 28, 2024

Credits offered: CME

Estimate time of completion: 1 hour

Course must be completed by the expiration date

Course Description

Therapy-related neoplasms are recognized as a late effect of genotoxic exposure (cytotoxic chemotherapy or irradiation as a treatment for primary malignancy) or complication after solid organ transplant or treatment of autoimmune disorder. The importance of recognition of this type of neoplasms in oncology testing will be discussed in this session through a series of representative cases. These illustrative cases will demonstrate the utility of various axillary testing types in identification of markers associated with specific prognosis in this type of cancer and treatment options.

Target Audience

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.

Learning Objectives

At the conclusion of this session, participants should be able to:

1. Discuss the clinicopathologic features of therapy-related neoplasms of myeloid and lymphoid origin.
2. Identify genetic factors predisposing to therapy-related complications.
3. Discuss the current status of clinical management of therapy-related neoplasms.

Moderator:

Beth Pitel, M.S., CG(ASCP) CM

Clinical Variant Scientist, Assistant Professor in Division of Laboratory Genetics and Genomics

Presenters:

Yasmin Abaza, MD

Assistant Professor of Medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University

Dr. Yasmin Abaza earned her medical degree from University of Alexandria, Egypt and completed her Internal Medicine residency training at Florida Hospital Medical Center. She then completed two fellowships in Hematology/Oncology and Leukemia at UCLA and MD Anderson Cancer Center, respectively. She joined the Division of Hematology and Oncology, Leukemia Program, at Northwestern University in September 2020. Her research focuses on targeted therapies for patients with myeloid.

Juehua Gao, MD, PhD

Associate Professor of Pathology (Hematopathology), Feinberg School of Medicine, Northwestern University

Dr. Gao is an Associate Professor of Pathology at Northwestern University Feinberg School of Medicine. She earned her MD degree from Fudan University Shanghai College of Medicine in China, and PhD degree in Immunology from University of Florida. She completed her Anatomic and Clinical pathology residency, Hematopathology and Molecular Pathology fellowships at Northwestern University McGraw Medical Centre. She is board certified in Anatomic and Clinical pathology, Hematology and Molecular Genetic Pathology by American Board of Pathology. The focus of her clinical practice and research is hematologic malignancy.

Madina Sukhanova, PhD, FACMG

Assistant Professor of Pathology (Molecular Pathology), Feinberg School of Medicine, Northwestern University.

Dr. Madina Sukhanova earned her PhD degree in genetics from the Institute of Cytology and Genetics, Novosibirsk University, Russia and completed her clinical cytogenetics and molecular genetics fellowships at the University of Chicago. She has been with Division of Molecular Pathology at Northwestern Memorial Hospital since 2018 where she is the co-director of the cytogenetics laboratory and assistant technical director of molecular diagnostics laboratory. Her research work focuses on evidence-based subclassification of high-risk hematologic malignancies and identification of genetic markers of potential therapeutic significance.

Planning Committee:

Beth Pitel, MS, CG(ASCP)
Gordana Raca, MD, PhD, FACMG
Manuela Benary, PhD
Jason Saliba, PhD
Jane Radford, MHA, CHCP  

Continuing Medical Education (CME AMA & CME Other)

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming your Educational Credits

This activity consists of: View content, take a post-test, the test may be taken as often as necessary to achieve a passing score of 80% or better is required to receive credit.  If you do not achieve a passing score, the program will identify which questions you answered incorrectly so that you can review the module and try again. Complete the evaluation form.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

• Financial Disclosures and Mitigation Procedure
• ACMG Content Validation Policy
• ACMG Content Branding Policy

All of the relevant financial relationships listed for these individuals have been mitigated.